Advertisement

Aggression

  • Kari HarperEmail author
Chapter

Abstract

Aggression, self-injurious behavior, and behavior changes are reported in many patients with intellectual disability and are the chief complaint or a complicating factor in many healthcare visits. When evaluating patients with intellectual disability, it is important to consider biological, psychological, and social factors that may contribute to aggressive behaviors including medical problems, pain, grief, reaction to change, feeling unsafe, and psychiatric disorders, among others. The biopsychosocial model in evaluation emphasizes a calm environment, an evolving approach, and a thorough evaluation including history, risk factors, and collateral sources. This chapter provides information on common presentations of behaviors and considerations of medical conditions, medical workup, and information gathering from caregivers and the patient. It also provides up-to-date information on both non-pharmacological and pharmacological treatment of aggression in the ID population. When using a pharmacological intervention, it is important to consider underlying conditions as well as comorbidities and side effects when making a medication choice. While antipsychotics are the most widely used, there is evidence that other, potentially less harmful medications can be helpful, especially when there is an underlying mood or anxiety disorder or underlying ADHD. It is also important to consider lowering the dose of medication or discontinuing the medication when able, as research has shown success in doing so without return of aggressive behavior.

Keywords

Aggression Violence Self-injury Self-harm Intellectual disability Autism Biopsychosocial model Antipsychotic Mood stabilizer Antidepressant 

References

  1. 1.
    Capone GT, Brecher L, Bay M. Guanfacine use in children with down syndrome and comorbid attention-deficit hyperactivity disorder (ADHD) with disruptive behaviors. J Child Neurol. 2016;31(8):957–64.  https://doi.org/10.1177/0883073816634854.CrossRefPubMedGoogle Scholar
  2. 2.
    de Kuijper G, Evenhuis H, Minderaa RB, Hoekstra PJ. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. J Intellect Disabil Res. 2014;58(1):71–83.  https://doi.org/10.1111/j.1365-2788.2012.01631.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review. Res Develop Disabil. 2014;35(3):711–25.  https://doi.org/10.1016/j.ridd.2013.12.004.CrossRefGoogle Scholar
  4. 4.
    Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology. 2011;216(1):85–90.  https://doi.org/10.1007/s00213-011-2194-7.CrossRefPubMedGoogle Scholar
  5. 5.
    Gentile JP, Gillig PM, editors. Psychiatry of intellectual disability: a practical manual. Hoboken: John Wiley & Sons; 2012.Google Scholar
  6. 6.
    Harat M, Rudas M, Zielinski P, Birska J, Sokal P. Deep brain stimulation in pathological aggression. Stereotact Funct Neurosurg. 2015;93(5):310–5.  https://doi.org/10.1159/000431373.CrossRefPubMedGoogle Scholar
  7. 7.
    Loebel A, Brams M, Goldman RS, Silva R, Hernandez D, Deng L, Mankoski R, Findling RL. Lurasidone for the treatment of irritability associated with autistic disorder. J Autism Dev Disord. 2016;46(4):1153–63.  https://doi.org/10.1007/s10803-015-2628-x.CrossRefPubMedGoogle Scholar
  8. 8.
    McNamara R, Randell E, Gillespie D, Wood F, Felce D, Romeo R, Angel L, Espinasse A, Hood K, Davies A, Meek A, Addison K, Jones G, Deslandes P, Allen D, Knapp M, Thapar A, Kerr M. A pilot randomised controlled trial of community-led ANtipsychotic drug REduction for adults with learning disabilities. Health Technol Assess (Winchester, England). 2017;21(47):1–92.  https://doi.org/10.3310/hta21470.CrossRefGoogle Scholar
  9. 9.
    Ming X, Gordon E, Kang N, Wagner GC. Use of clonidine in children with autism spectrum disorders. Brain Dev. 2008;30(7):454–60.  https://doi.org/10.1016/j.braindev.2007.12.007.CrossRefPubMedGoogle Scholar
  10. 10.
    Patel BD, Barzman DH. Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review. Psychiatr Q. 2013;84(4):407–15.  https://doi.org/10.1007/s11126-013-9253-7.CrossRefPubMedGoogle Scholar
  11. 11.
    Politte LC, McDougle CJ. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology. 2014;231(6):1023–36.  https://doi.org/10.1007/s00213-013-3068-y.CrossRefPubMedGoogle Scholar
  12. 12.
    Scheifes A, Walraven S, Stolker JJ, Nijman HL, Egberts TC, Heerdink ER. Adverse events and the relation with quality of life in adults with intellectual disability and challenging behaviour using psychotropic drugs. Res Dev Disabil. 2016;49-50:13–21.  https://doi.org/10.1016/j.ridd.2015.11.017.CrossRefPubMedGoogle Scholar
  13. 13.
    Stutzman D, Dopheide J. Acetylcysteine for treatment of autism spectrum disorder symptoms. Am J Health-Syst Pharm. 2015;72(22):1956–9.  https://doi.org/10.2146/ajhp150072.CrossRefPubMedGoogle Scholar
  14. 14.
    Sunovion receives FSA approval of supplemental new drug application (SNDA) for use of latuda® (LURASIDONE HCI) in the treatment of bipolar depression in pediatric patients (10 to 17 years of age) (2018). Retrieved from http://news.sunovion.com/press-release/sunovion-receives-fda-approval-supplemental-new-drug-application-snda-use-latuda
  15. 15.
    Taylor JL, Novaco RW, Brown T. Reductions in aggression and violence following cognitive behavioural anger treatment for detained patients with intellectual disabilities. J Intellect Disabil Res. 2016;60(2):126–33.  https://doi.org/10.1111/jir.12220.CrossRefPubMedGoogle Scholar
  16. 16.
    U. S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. (2015). Antidepressant medications: use in pediatric patients. Retrieved from https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf
  17. 17.
    U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. (2013). Atypical antipsychotic medications: use in pediatric patients. Retrieved from https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/atyp-antipsych-pediatric-factsheet11-14.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Wright State Psychiatry, Boonshoft School of Medicine, Wright State UniversityDaytonUSA

Personalised recommendations